Login
$CHRS
$0.51 +$0.00 (0.81%) After hours

$CHRS SEC Filings

Filed On Filing
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development –

29 Oct 2026 8-K: Regulation FD Disclosure; Other Events

-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients-

28 Aug 2026 8-K: Other Events

Coherus Oncology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

28 Aug 2026 424B5
28 Aug 2026 424B3
17 Aug 2026 8-K: Regulation FD Disclosure; Other Events

THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of August 17, 2026, is entered into by and between Coherus Oncology, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC, a New York limited li...

17 Aug 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a...

05 Aug 2026 S-8
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

27 Jul 2026 SCHEDULE 13G
15 Jun 2026 8-K: Changes in Registrant's Certifying Accountant

We have read Item 4.01 of Form 8-K dated June 12, 2026, of Coherus Oncology, Inc. and are in agreement with the statements contained in the first, second, third and fourth paragraphs on page 1 therein. We have no basis to agree or disagr...

09 Jun 2026 Form 4: Satvat Ali J., Director

Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy)

09 Jun 2026 Form 4: Karachun Rita A, Director

Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy)

09 Jun 2026 Form 4: Newcomer Lee Nisley, Director

Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy)

09 Jun 2026 Form 4: Ryan Michael Lee, Director

Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy)

09 Jun 2026 Form 4: O'Donnell-Tormey Jill, Director

Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy)

09 Jun 2026 Form 4: Wahlstrom Mats, Director

Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy)

09 Jun 2026 Form 4: Newton Charles W., Director

Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support